4.7 Article

Exendin-(9-39) Effects on Glucose and Insulin in Children With Congenital Hyperinsulinism During Fasting and During a Meal and a Protein Challenge

Journal

DIABETES CARE
Volume 45, Issue 6, Pages 1381-1390

Publisher

AMER DIABETES ASSOC
DOI: 10.2337/dc21-2009

Keywords

-

Funding

  1. National Institutes of Health [1R01FD004095-01A1]
  2. National Center for Research Resources grant [UL1RR024134]
  3. Clifford and Katherine Goldsmith Foundation

Ask authors/readers for more resources

The aim of this study was to assess the effects of exendin-(9-39) on fasting and postprandial plasma glucose and the incidence of hypoglycemia in children with hyperinsulinism. The results showed that exendin-(9-39) significantly increased fasting and postprandial glucose and reduced the likelihood of hypoglycemia.
OBJECTIVE The aim of this study was to assess whether exendin-(9-39) will increase fasting and postprandial plasma glucose and decrease the incidence of hypoglycemia in children with hyperinsulinism (HI). RESEARCH DESIGN AND METHODS This was an open-label, four-period crossover study. In periods 1 and 2, the effect of three different dosing regimens of exendin-(9-39) (group 1, 0.28 mg/kg; group 2, 0.44 mg/kg; group 3, 0.6 mg/kg) versus vehicle on fasting glucose was assessed in 16 children with HI. In periods 3 and 4, a subset of eight subjects received either vehicle or exendin-(9-39) (0.6 mg/kg) during a mixed-meal tolerance test (MMTT) and an oral protein tolerance test (OPTT). RESULTS Treatment group 2 showed 20% (P=0.037) increase in the area under the curve (AUC) of fasting glucose. A significant increase in AUC of glucose was also observed during the MMTT and OPTT; treatment with exendin-(9-39) resulted in 28% (P <= 0.001) and 30% (P=0.01) increase in AUC of glucose, respectively. Fasting AUC of insulin decreased by 57% (P=0.009) in group 3. In contrast, AUC of insulin was unchanged during the MMTT and almost twofold higher (P=0.004) during the OPTT with exendin-(9-39) treatment. In comparison with vehicle, infusion of exendin-(9-39) resulted in significant reduction in likelihood of hypoglycemia in group 2, by 76% (P=0.009), and in group 3, by 84% (P=0.014). Administration of exendin-(9-39) during the OPTT resulted in 82% (P=0.007) reduction in the likelihood of hypoglycemia. CONCLUSIONS These results support a therapeutic potential of exendin-(9-39) to prevent fasting and protein-induced hypoglycemia in children with HI.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available